Your browser doesn't support javascript.
loading
Cost-effectiveness of elbasvir/grazoprevir use in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease in the United States.
Elbasha, E; Greaves, W; Roth, D; Nwankwo, C.
Affiliation
  • Elbasha E; Merck & Co., Inc., Kenilworth, NJ, USA.
  • Greaves W; Merck & Co., Inc., Kenilworth, NJ, USA.
  • Roth D; University of Miami Miller School of Medicine, Miami, FL, USA.
  • Nwankwo C; Merck & Co., Inc., Kenilworth, NJ, USA.
J Viral Hepat ; 24(4): 268-279, 2017 04.
Article in En | MEDLINE | ID: mdl-27966249
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antiviral Agents / Quinoxalines / Benzofurans / Cost-Benefit Analysis / Hepacivirus / Hepatitis C, Chronic / Renal Insufficiency, Chronic / Imidazoles Type of study: Health_economic_evaluation / Prognostic_studies Aspects: Patient_preference Limits: Humans Country/Region as subject: America do norte Language: En Journal: J Viral Hepat Journal subject: GASTROENTEROLOGIA Year: 2017 Document type: Article Affiliation country: Estados Unidos Country of publication: Reino Unido
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antiviral Agents / Quinoxalines / Benzofurans / Cost-Benefit Analysis / Hepacivirus / Hepatitis C, Chronic / Renal Insufficiency, Chronic / Imidazoles Type of study: Health_economic_evaluation / Prognostic_studies Aspects: Patient_preference Limits: Humans Country/Region as subject: America do norte Language: En Journal: J Viral Hepat Journal subject: GASTROENTEROLOGIA Year: 2017 Document type: Article Affiliation country: Estados Unidos Country of publication: Reino Unido